Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC

NCT06912087 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Neoplasms
Carcinoma, Squamous Cell
Neoplasm Recurrence, Local
Neoplasm Metastasis
Recurrent Squamous Cell Carcinoma
Metastatic Squamous Cell Carcinoma

Interventions

DRUG: Zanzalintinib
DRUG: Cetuximab
DRUG: Pembrolizumab

Sponsor

University of Chicago

Collaborators

[object Object]